SCHEMBL10104503

SCHEMBL10104503

Cc1cc(CN(C)C)c(C)c(C(F)(F)F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
SLC6A4 P31645 9/20 0.38
HTR2A P28223 2/20 0.38
KCNH2 Q12809 2/20 0.38
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
G6PD P11413 1/20 0.36
PABPC1 P11940 1/20 0.36
KMT2A Q03164 1/20 0.36
HKDC1 Q2TB90 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GLA P06280 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104437 0.82 SLC6A4 (0.42) CYP3A4CYP2D6SLC6A4HTR2AKCNH2
SCHEMBL10104537 0.80 SLC6A4 (0.37) CYP3A4CYP2D6SLC6A4HTR2AKCNH2
SCHEMBL10104510 0.78 SLC6A2 (0.36) SLC6A4KDM4EMEN1ALDH1A1GAA
SCHEMBL13960088 0.78 SLC6A4 (0.46) CYP3A4CYP2D6SLC6A4HTR2AKCNH2
SCHEMBL91657 0.75 SMN1; SMN2 (0.40) CYP3A4CYP2D6HTR2AMEN1ALDH1A1
SCHEMBL23239896 0.71 SLC6A4 (0.46) SLC6A4HTR2AKCNH2KDM4EMEN1
SCHEMBL10104376 0.70 TP53 (0.32) CYP2D6SLC6A4KCNH2MEN1MAPT
SCHEMBL10104533 0.69 KDM4E (0.44) CYP3A4CYP2D6KDM4EMEN1ALDH1A1
SCHEMBL11002684 0.69 HSPA5 (0.68) CYP2D6KDM4EMEN1ALDH1A1POLB
SCHEMBL13550098 0.69 RAPGEF4 (0.41) CYP3A4CYP2D6MEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 CYP3A4 1111/4885CYP2D6 554/4885SLC6A4 4238/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 CYP3A4 688/4885CYP2D6 470/4885SLC6A4 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.